Back to Search
Start Over
Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC
- Source :
- Oncology Research and Treatment, 41(Suppl.4):V849, 271-271. KARGER, Hochmair, M, Ahn, M-J, Camidge, D R, Tiseo, M, Reckamp, K, Hansen, H K, Kim, S-W, Huber, R, West, H, Groen, H, Leighl, N, Gettinger, S, Langer, C, Paz-Ares Rodriguez, L, Smit, E, Kim, E, Reichmann, W, Kerstein, D & Kim, D-W 2018, ' Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC ', Oncology Research and Treatment, vol. 41, no. Suppl. 4, pp. 271 .
- Publication Year :
- 2018
Details
- Language :
- English
- ISSN :
- 22965270
- Database :
- OpenAIRE
- Journal :
- Oncology Research and Treatment, 41(Suppl.4):V849, 271-271. KARGER, Hochmair, M, Ahn, M-J, Camidge, D R, Tiseo, M, Reckamp, K, Hansen, H K, Kim, S-W, Huber, R, West, H, Groen, H, Leighl, N, Gettinger, S, Langer, C, Paz-Ares Rodriguez, L, Smit, E, Kim, E, Reichmann, W, Kerstein, D & Kim, D-W 2018, ' Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC ', Oncology Research and Treatment, vol. 41, no. Suppl. 4, pp. 271 .
- Accession number :
- edsair.dedup.wf.001..14a4e52a8201d69c462c533cfb0be9fd